Short Interest in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Grows By 330.5%

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) saw a large increase in short interest in June. As of June 15th, there was short interest totaling 16,744 shares, an increase of 330.5% from the May 31st total of 3,889 shares. Based on an average daily volume of 2,088 shares, the short-interest ratio is currently 8.0 days. Currently, 9.8% of the shares of the stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Amplify Weight Loss Drug & Treatment ETF stock. Cravens & Co Advisors LLC purchased a new stake in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,023 shares of the company’s stock, valued at approximately $390,000. Cravens & Co Advisors LLC owned approximately 10.02% of Amplify Weight Loss Drug & Treatment ETF as of its most recent filing with the Securities and Exchange Commission (SEC).

Amplify Weight Loss Drug & Treatment ETF Price Performance

Shares of THNR traded up $0.42 during mid-day trading on Friday, hitting $25.36. The company’s stock had a trading volume of 2,062 shares, compared to its average volume of 2,102. The firm has a 50-day moving average price of $24.50 and a 200 day moving average price of $25.10. Amplify Weight Loss Drug & Treatment ETF has a fifty-two week low of $21.70 and a fifty-two week high of $27.28. The stock has a market capitalization of $4.31 million, a price-to-earnings ratio of 24.31 and a beta of 0.40.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.